PORT WASHINGTON, N.Y. – April 26, 2016 – Pall Life Sciences Biopharmaceutical division of global filtration, separation, and purification leader Pall Corporation, is pleased to announce the commercial launch of the CadenceTM Acoustic Separator (CAS), which applies acoustic wave separation technology in a novel single-use format for the clarification of cell culture bioprocess fluids. The CAS delivers robust, reliable cell and protein yields in a closed system without centrifugation, while drastically reducing user cost and risk. The CAS is available for immediate ordering and shipment, and has also been designed to be easily integrated with other Pall Life Sciences products to enable continuous bioprocessing.
“We launched our continuous processing vision at the end of 2015, introducing the concept of acoustic wave separation technology as an enabling tool for customers to bridge the critical gap between the bioreactor and the downstream processing train. We have now brought that concept to fruition with the commercial launch of the CAS as the first in a series of product launches that enable continuous bioprocessing,” said Vice President and General Manager of Biopharmaceuticals, Michael Egholm, Ph.D. “The CAS technology is truly revolutionary, eliminating reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and creating a continuous feed stream for direct integration with our full portfolio.”
Pall Life Sciences obtained an exclusive license to acoustic wave separation technology in June 2015 from FloDesign Sonics (FDS). The CAS works via acoustic forces that are applied across a countercurrent flow of bioprocess fluid, generating three-dimensional standing waves that trap cells at their nodes. This leads to aggregation and precipitation from suspension, thereby “trapping” the cells for simple extraction. The CAS is capable of clarifying many types of biologic products, including recombinant therapeutic proteins and monoclonal antibodies, regardless of the variability in particulate concentrations and cell culture density, turbidity and viability.
The CAS is part of the  Cadence product portfolio, which features enabling technologies for key unit operations required in the continuous production of monoclonal antibodies and other recombinant proteins. The Cadence portfolio leverages the benefits of single-use technologies to feature integrated, end to end biomanufacturing solutions that increase productivity and decrease risk for customers.
To learn more about the CAS, or to see it is action, visit the following links:
CAS Video: https://www.youtube.com/watch?v=YOr7AGGx3MI
Pall Life Sciences Continuous Portfolio: http://www.pall.com/main/biopharmaceuticals/continuous
Dr. Michael Egholm on Continuous Processing: https://www.youtube.com/watch?v=_tY_4NemRLU
The CAS will be on display in New York, NY at INTERPHEX this week from April 26 to 28 in booth 2815. It will be featured amongst a host of enabling Pall Life Sciences technologies at the booth, and is the subject of many talks during the show. Find the team’s full INTERPHEX agenda here: http://www.pall.com/main/about-us/event-details.page?id=20160203112651
Pall Corporation provides critical fluid management solutions to global life sciences and industrial manufacturing customers. The biopharm division of Pall Life Sciences features an unmatched portfolio of traditional and single-use products with custom service support from R&D to clinical phases to production. Pall is committed to continuously improving bioprocesses to enable users to advance global health with safe, environmentally responsible technologies. Stay up to date with our latest progress at: www.pall.comLinkedInTwitter; and YouTube.

Press Contact
Beth Willers, White Matter Communications


Pall Life Sciences Marketing Contact
Erin C. Bush, MBA
Senior Manager, Global Product Marketing

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development